The European Hematology Association 24th congress EHA 2019
![The European Hematology Association 24th congress EHA 2019](/images/conferences/24th-congress-of-eha_20181106113126_big.jpeg)
Programme du congrès
Lieu : Amsterdam
Pays : Pays-Bas
Langue : ENG
Date de début :
Date de fin :
Spécialités : Hématologie
The congress also provides you with the opportunity to attend satellite programs, Updates-in-Hematology and to visit the exhibition organized by pharmaceutical companies.
Novel immunotherapy 5F9+rituximab well tolerated with rapid and durable responses
![Novel immunotherapy 5F9+rituximab well tolerated with rapid and durable responses Novel immunotherapy 5F9+rituximab well tolerated with rapid and durable responses](/images/videos/novel-immunotherapy-5f9-rituximab-well-tolerated-with-rapid-and-durable-responses_20190628152926.png)
- Date : 13/06/2019
- 1 0
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients
![Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients](/images/videos/dasatinib-blinatumomab-combination-for-the-front-line-treatment-of-adult-ph-positive-all-patients_20190628152638.png)
- Date : 13/06/2019
- 0 0
PET after 2 cycles of ABVD in patients with early-stage favourable hodgkin lymphoma
![PET after 2 cycles of ABVD in patients with early-stage favourable hodgkin lymphoma PET after 2 cycles of ABVD in patients with early-stage favourable hodgkin lymphoma](/images/videos/pet-after-2-cycles-of-abvd-in-patients-with-early-stage-favourable-hodgkin-lymphoma_20190628152509.png)
- Date : 13/06/2019
- 0 0
Echelon-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy
![Echelon-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy Echelon-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy](/images/videos/echelon-1-study-3-year-update-frontline-brentuximab-vedotin-with-chemotherapy_20190628152329.png)
- Date : 13/06/2019
- 0 0
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy
![CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy](/images/videos/cd-19-mutation-frequency-after-blinatumomab-treatment-is-lower-than-after-car-t-cell-therapy_20190628151559.png)
- Date : 13/06/2019
- 0 0
Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities
![Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities](/images/videos/comment-on-fixed-duration-venetoclax-plus-obinutuzumab-in-patients-with-cll-and-comorbidities_20190628150952.png)
- Date : 13/06/2019
- 0 0
Safety and efficacy of escalating doses of the hu5f9-g4 with rituximab in patients
![Safety and efficacy of escalating doses of the hu5f9-g4 with rituximab in patients Safety and efficacy of escalating doses of the hu5f9-g4 with rituximab in patients](/images/videos/safety-and-efficacy-of-escalating-doses-of-the-hu5f9-g4-with-rituximab-in-patients_20190628151113.png)
- Date : 13/06/2019
- 0 0
AlloHCT conditioning intensity in AML in complete remission with residual disease
![AlloHCT conditioning intensity in AML in complete remission with residual disease AlloHCT conditioning intensity in AML in complete remission with residual disease](/images/videos/allohct-conditioning-intensity-in-aml-in-complete-remission-with-residual-disease_20190628151325.png)
- Date : 13/06/2019
- 0 0
CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML
![CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML](/images/videos/cd33-t-cell-recruiting-antibody-constructs-for-treatment-of-relapsed-refractory-aml_20190628151440.png)
- Date : 13/06/2019
- 0 0
Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for B-ALL
![Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for B-ALL Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for B-ALL](/images/videos/controlling-crs-related-coagulopathy-improves-the-safety-of-car-t-cell-therapy-for-b-all_20190628151636.png)
- Date : 13/06/2019
- 0 0
ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone
![ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone](/images/videos/icaria-results-treating-rrmm-patients-with-isatuximab-pomalidomide-and-low-dose-dexamethasone_20190628151759.png)
- Date : 13/06/2019
- 0 0
HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab
![HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab](/images/videos/horizon-update-using-melflufen-to-treat-rrmm-patients-refractory-to-daratumumab_20190628151821.png)
- Date : 13/06/2019
- 0 0